Dr. Hsiao is the Chief Executive Officer, President and Co-Founder at Acepodia. Dr. Hsiao has extensive research experiences in immune cell therapies, which lead to the discovery of components of ACC™ (Antibody-Cell Conjugation) technology to the invention of the novel cellular immunotherapy, ACE™ (Antibody-Cell Conjugation Effector cells). Dr. Hsiao earned his BS in Chemistry from National Taiwan University, and his PhD in Chemistry and Molecular Cell Biology from the University of California, Berkeley.